Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Chronic Myeloid Leukaemia Patients with Stable Molecular Responses (at least MR3) May Safely Decrease the Dose of Their Tyrosine Kinase Inhibitor: Data from the British Destiny Study

Richard E. Clark, MD, Fotios Polydoros, MSc, Jane F. Apperley, MD, Christopher Pocock, Graeme Smith, MD, Jenny L Byrne, FRCP FRCPath PhD, Stephen G. O'Brien, BSc (Hons) PhD MBChB FRCP MRCPath, Tony Coffey, Letizia Foroni, MD PhD, Mhairi Copland, BSc (Hons) MB ChB PhDFRCP FRCPath

Blood (2016) 128 (22): 938.

https://doi.org/10.1182/blood.V128.22.938.938

Published: 2016

Journal Articles

Social Inequality Is An Important Risk Factor For Death From Chronic Myeloid Leukaemia: Findings From a UK Population-Based Cohort

Alexandra Smith, PhD, Eve Roman, PhD, Daniel Painter, BSc, Debra Howell, PhD, Graeme Smith, MD, Paul Evans, Russell Patmore, MD, Andrew Jack, PhD

Blood (2013) 122 (21): 4036.

https://doi.org/10.1182/blood.V122.21.4036.4036

Published: 2013

Journal Articles

Rituximab Purging and Maintenance Improves Progression Free Survival but Not Overall Survival In Patients with Relapsed or Resistant Follicular Lymphoma Prior Receiving An Autologous Transplant

Ruth Pettengell, MD, Norbert Schmitz, MD, Christian Gisselbrecht, MD, Graeme Smith, MD, William N Patton, MD, Bernd Metzner, MD, Dolores Caballero, MD, Herve Tilly, MD, Jan A Walewski, MD, Isabelle Bence-Bruckler, MD, Bik To, MD, Christian H. Geisler, MD, Rik Schots, MD, Eva Kimby, MD, Christian J. Taverna, MD, T. Kozak, MD, Ruzena Uddin, MSci, Carmen Ruiz de Elvira, PhD, Anthony H. Goldstone, MD

Blood (2010) 116 (21): 3567.

https://doi.org/10.1182/blood.V116.21.3567.3567

Published: 2010

Journal Articles

Impact of Prior Therapy and Suboptimal Response to Imatinib On the Efficacy and Safety of Nilotinib Among 1,422 Patients with Imatinib-Resistant or —Intolerant Chronic Myeloid Leukemia (CML) in Chronic Phase (CP): Sub-Analyses of the ENACT (Expanding Nilotinib Access in Clinical Trials) Study.

Franck Emmanuel Nicolini, MD, PhD, Dong-Wook Kim, MD, PhD, Bernadeta Ceglarek, Anna Turkina, Giuliana Alimena, Haifa Kathrin Al-Ali, MD, Zhixiang Shen, Saengsuree Jootar, MD, Graeme Smith, MD, Carmino Antonio De Souza, MD, PhD, Pedro Enrique Dorlhiac-Llacer, David A. Rizzieri, MD, Tomasz Szczudlo, MD, Myriam Berton, Jim Wang, PhD, Christine Bieri, MBA, Philipp D. le Coutre, MD

Blood (2009) 114 (22): 2201.

https://doi.org/10.1182/blood.V114.22.2201.2201

Published: 2009

Journal Articles

Patterns and Management of Selected Adverse Events of Adult Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia (CML) From the ENACT (Expanding Nilotinib Access in Clinical Trials) Study.

Philipp D. le Coutre, MD, Bernadeta Ceglarek, Anna Turkina, Dong-Wook Kim, MD, PhD, Giuliana Alimena, Haifa Kathrin Al-Ali, MD, Zhixiang Shen, Saengsuree Jootar, MD, Graeme Smith, MD, Carmino Antonio De Souza, MD, PhD, David A Rizzieri, MD, Tomasz Szczudlo, MD, Myriam Berton, Jim Wang, PhD, Ellison Dial, MBA, Franck Emmanuel Nicolini, MD, PhD

Blood (2009) 114 (22): 1115.

https://doi.org/10.1182/blood.V114.22.1115.1115

Published: 2009

Journal Articles

Efficacy and Safety of Nilotinib in Elderly Patients with Imatinib-Resistant or -;Intolerant Chronic Myeloid Leukemia (CML) in Chronic Phase (CP): A Sub-Analysis of the ENACT (Expanding Nilotinib Access in Clinical Trials) Study.

Philipp D. le Coutre, MD, Anna Turkina, Dong-Wook Kim, MD, PhD, Bernadeta Ceglarek, Giuliana Alimena, Haifa Kathrin Al-Ali, MD, Zhixiang Shen, Saengsuree Jootar, MD, Graeme Smith, MD, Carmino Antonio De Souza, MD, PhD, Pedro Enrique Dorlhiac-Llacer, David A Rizzieri, MD, Tomasz Szczudlo, MD, Myriam Berton, Jim Wang, PhD, Si-Tien Wang, Franck Emmanuel Nicolini, MD, PhD

Blood (2009) 114 (22): 3286.

https://doi.org/10.1182/blood.V114.22.3286.3286

Published: 2009

Journal Articles

Expanding Nilotinib Access in Clinical Trials (ENACT) Study in Adult Patients (Pts) with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia (CML) in Blast Crisis (BC), Accelerated Phase (AP), or Chronic Phase (CP): Preliminary Safety Analysis.

Franck Nicolini, MD, Giuliana Alimena, MD, Haifa-Kathrin Al-Ali, MD, Andrey Zaritskey, Zhixiang Shen, MD, Saengsuree Jootar, MD, Graeme Smith, MD, Yanzhi Hsu, Maria Luisa Veronese, David A. Rizzieri

Blood (2007) 110 (11): 2960.

https://doi.org/10.1182/blood.V110.11.2960.2960

Published: 2007

Journal Articles

Prophylactic Low Molecular Weight Heparin (LMWH) during Pregnancy Is Not Associated with a Decrease in Bone Mineral Density (BMD). The TIPPS (Thrombophilia in Pregnancy Prophylaxis Study) BMD Substudy.

Marc A. Rodger, MD, MSc, Alejandro Lazo-Langner, MD, Susan Kahn, MD, MSc, Michael Kovacs, MD, Sue Robinson, MD, Mark Blostein, MD, Graeme Smith, MD, John Kingdom, MD, Christine Demers, MD, Susan Solymoss, MD, Rshmi Khurana, MD, Evelyn Rey, MD, Anne Marie Clement, RN, Philip S. Wells, MD, MSc

Blood (2005) 106 (11): 548.

https://doi.org/10.1182/blood.V106.11.548.548

Published: 2005

Journal Articles

Imatinib Followed by Reduced Intensity Stem Cell Transplantation and Donor Lymphocyte Infusions Is Effective in Chronic Phase CML with Less Toxicity Than Standard Allogeneic Transplantation.

Mhairi Copland, MD, Nicholas Heaney, MD, Karen Stewart, BSc, Judith Godden, PhD, Graeme Smith, MD, Charles Crawley, MD, Tessa L. Holyoake, MD, PhD

Blood (2005) 106 (11): 1125.

https://doi.org/10.1182/blood.V106.11.1125.1125

Published: 2005

NARROW

Chronic Myeloid Leukaemia Patients with Stable Molecular Responses (at least MR3) May Safely Decrease the Dose of Their Tyrosine Kinase Inhibitor: Data from the British Destiny Study

Social Inequality Is An Important Risk Factor For Death From Chronic Myeloid Leukaemia: Findings From a UK Population-Based Cohort

Rituximab Purging and Maintenance Improves Progression Free Survival but Not Overall Survival In Patients with Relapsed or Resistant Follicular Lymphoma Prior Receiving An Autologous Transplant

Impact of Prior Therapy and Suboptimal Response to Imatinib On the Efficacy and Safety of Nilotinib Among 1,422 Patients with Imatinib-Resistant or —Intolerant Chronic Myeloid Leukemia (CML) in Chronic Phase (CP): Sub-Analyses of the ENACT (Expanding Nilotinib Access in Clinical Trials) Study.

Patterns and Management of Selected Adverse Events of Adult Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia (CML) From the ENACT (Expanding Nilotinib Access in Clinical Trials) Study.

Efficacy and Safety of Nilotinib in Elderly Patients with Imatinib-Resistant or -;Intolerant Chronic Myeloid Leukemia (CML) in Chronic Phase (CP): A Sub-Analysis of the ENACT (Expanding Nilotinib Access in Clinical Trials) Study.

Expanding Nilotinib Access in Clinical Trials (ENACT) Study in Adult Patients (Pts) with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia (CML) in Blast Crisis (BC), Accelerated Phase (AP), or Chronic Phase (CP): Preliminary Safety Analysis.

Prophylactic Low Molecular Weight Heparin (LMWH) during Pregnancy Is Not Associated with a Decrease in Bone Mineral Density (BMD). The TIPPS (Thrombophilia in Pregnancy Prophylaxis Study) BMD Substudy.

Imatinib Followed by Reduced Intensity Stem Cell Transplantation and Donor Lymphocyte Infusions Is Effective in Chronic Phase CML with Less Toxicity Than Standard Allogeneic Transplantation.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only